Polyclonal Antibody to Aconitase 1 (ACO1)
| Code | Size | Price |
|---|
| PAJ683Hu02-20ul | 20ul | £87.00 |
Quantity:
| PAJ683Hu02-100ul | 100ul | £162.00 |
Quantity:
| PAJ683Hu02-200ul | 200ul | £218.00 |
Quantity:
| PAJ683Hu02-1ml | 1ml | £499.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
IREB1; IRP1; IREBP; Iron regulatory protein 1; Iron-responsive element-binding protein 1; Cytoplasmic aconitate hydratase; Citrate hydro-lyase; Ferritin repressor protein
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Aconitase 1
Reactivity:
Mu;Ra;Po;
Source:
Polyclonal antibody preparation
Usage:
Western blotting: 1-5ug/mL<br/>Immunocytochemistry in formalin fixed cells: 5-20ug/mL<br/>Immunohistochemistry in formalin fixed frozen section: 5-20ug/mL<br/>Immunohistochemistry in paraffin section: 5-20ug/mL<br/>Enzyme-linked Immunosorbent Assay: 0.05-2ug/mL<br/>Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Aconitase 1 (ACO1) | RPJ683Hu02 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||